Enfamil Growth Paces Strong Nutritionals Performance For Bristol-Myers
This article was originally published in The Tan Sheet
Executive Summary
Bristol-Myers Squibb's Enfamil infant formula brand posted sales growth of 24% to $175 mil. in the fourth quarter, contributing to a continued strong showing by the company's nutritional business. Quarterly sales in the U.S. increased 19% to $150 mil. For the year, Enfamil sales were up 13%, totaling $621 mil. worldwide, while U.S. sales rose 10% to $560 mil.